Bruce Booth is a partner at Atlas Venture and focuses on novel biopharmaceutical products, therapeutic platforms, and innovative biomedical technologies. Bruce is currently chairman of AVROBIO (NASDAQ:AVRO), Kymera Therapeutics, HotSpot Therapeutics, Nimbus Therapeutics, Rodin Therapeutics, and Unum Therapeutics (NASDAQ:UMRX), and he also serves on the board of Lysosomal Therapeutics. He previously served on the boards of past Atlas companies Avila (acquired by Celgene), Padlock (acquired by BMS), Prestwick (acquired by Biovail), Stromedix (acquired by Biogen), Zafgen (NASDAQ:ZFGN), and a number of other ventures.
Bruce also serves on the boards of the National Venture Capital Association, the Pennsylvania State Research Foundation, and New England Disabled Sports, a charity dedicated to adaptive sports.
Prior to joining Atlas in 2005, Bruce was a consultant at McKinsey & Company, as well as an investor for Caxton Health Holdings. As a British Marshall Scholar, Bruce received a DPhil (PhD) in molecular immunology from Oxford University. He received a BS in biochemistry, summa cum laude, from the Pennsylvania State University.